[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Second Hospital of Nanjing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":623},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,48,75,101,130,156,178,202,222,248,275,299,324,346,371,390,411,428,450,477,495,522,546,570,597],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100639705","gut-oxygen-therapy-for-ischemic-hypoxic-bowel-disease-100639705",false,"NCT07621367","Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease","Efficacy and Safety of Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study","Inclusion Criteria:\n\n* Clinical diagnosis of intestinal ischemia and hypoxia-related diseases caused by conditions such as ischemic bowel disease, heart failure, etc., presenting with recurrent or persistent abdominal pain and\u002For distension, and difficulty in defecation. Examples include: heart failure-related defecation difficulty, severe malnutrition combined with defecation difficulty, acute ischemic bowel disease, and chronic ischemic bowel disease.\n* At least able to perform bedside activities and able to defecate in conventional positions (sitting or squatting).\n* Age ≥18 years, and able to voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Acute intestinal emergencies such as acute intestinal obstruction, intestinal perforation, or active massive gastrointestinal bleeding.\n* Intestinal fistula.\n* History of abdominal surgery within the recent past (\\\u003C1 month).\n* Severe uncontrolled arrhythmia or respiratory failure.\n* Cardiac function Class IV (NYHA Class IV).\n* Patients with abnormal visceral pressure sensitivity.\n* Inability to cooperate with study assessments.\n* Other conditions that, in the opinion of the investigator, make the subject unsuitable for inclusion.","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, randomized, double-blind, placebo-controlled clinical trial aimed to investigate the efficacy and safety of gut oxygen therapy in the treatment of ischemic-hypoxic bowel disease using deep intestinal catheterization as a targeted route for gut oxygen delivery.",[27,28],"Ischemic Bowel Disease","Hypoxic Events",[30,31,32,33,34],"ischemic bowel disease","heart failure","abdominal pain","abdominal distension","difficult defecation","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":21},"2026-05-28",{"date":43,"type":21},"2031-05-19",{"name":45,"class":46},"The Second Hospital of Nanjing Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100635714","phase-1-study-of-cmts1215-injection-in-patients-with-solid-tumors-100635714","NCT07556276","Study of CMTS1215 Injection in Patients With Solid Tumors","A Prospective, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of CMTS1215 Injection in Subjects With Solid Tumors","Inclusion Criteria:\n\n1. Adults aged 18 years or older, any gender\n2. Histologically confirmed solid tumor with measurable lesions according to RECIST 1.1\n3. Failed or unable to complete conventional first-line, second-line, or third-line anti-tumor therapies, with multidisciplinary team consensus that no other suitable treatment options are available\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n5. Expected survival time \\> 3 months 6 Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n1. Uncontrolled cardiovascular disease (e.g., heart failure NYHA III-IV, coronary artery disease, cardiomyopathy, arrhythmia)\n2. Active severe clinical infection (\\> Grade 2 NCI-CTCAE v5.0), including fungal, viral, or tuberculosis infection\n3. Coagulation abnormalities with bleeding tendency (INR outside normal range without anticoagulants within 14 days prior to enrollment); patients on anticoagulants or vitamin K antagonists (warfarin, heparin, or similar)\n4. History of immunodeficiency, acquired or congenital immunodeficiency diseases, or organ transplantation\n5. Lactating female patients\n6. Currently participating in other clinical studies\n7. Women of childbearing potential planning pregnancy during the study period\n8. Patients with allergies to common antibiotics\n9. Patients lacking or with restricted legal capacity\n10. Other patients deemed unsuitable for enrollment by the investigator",{"count":56,"type":21},20,[58,59],"PHASE1","PHASE2","This is a prospective, open-label, single-arm exploratory clinical trial to evaluate the safety and efficacy of CMTS1215 (Proteus mirabilis) oncolytic bacteria injection for the treatment of solid tumors. The study aims to enroll at least 8 patients with histologically confirmed solid tumors who have failed or are unable to complete conventional first-line, second-line, or third-line anti-tumor therapies.",[62],"Solid Tumor",[64,65,66],"Solid tumor","Advanced cancer","Treatment-refractory cancer","2026-04-24",{"date":69,"type":39},"2026-04-29",{"date":71,"type":39},"2025-03-06",{"date":73,"type":21},"2030-12-31",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":47},"100607563","washed-microbiota-transplantation-for-food-intolerance-100607563","NCT07190183","Washed Microbiota Transplantation for Food Intolerance","Inclusion Criteria:\n\n1. Food intolerance occurs through laboratory examination of at least two main foods\n2. Underwent washed microbiota transplantation.\n\nExclusion Criteria:\n\n1. Expected survival time \\\u003C3 months;\n2. Women who are pregnant or breastfeeding;\n3. Other patients deemed not suitable for enrollment by the investigator.",{"count":82,"type":21},100,"3 Months","OBSERVATIONAL","Food intolerance (FI) is an adverse reaction to food caused by non-immune mechanisms, mainly related to digestive enzyme deficiencies (e.g. lactase deficiency), metabolic abnormalities (e.g. impaired absorption of fructose) or toxicity of food components (e.g. histamine). Unlike immune-mediated food allergy, FI symptoms are usually delayed (hours to days after ingestion) and mild, but are difficult to diagnose and manage clinically due to the complexity and variety of mechanisms that affect approximately 20% of the world's population.",[87],"Food Intolerance",[89,90,91,92],"washed microbiota transplantation","food intolerance","fecal microbiota transplantation","gut microbiota","2025-09-17",{"date":95,"type":39},"2025-09-24",{"date":97,"type":39},"2025-01-01",{"date":99,"type":21},"2035-12-31",{"name":45,"class":46},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100545010","phase-1-washed-microbiota-transplantation-for-attention-deficithyperactivity-disorder-100545010","NCT06376331","Washed Microbiota Transplantation for Attention-deficit\u002FHyperactivity Disorder","Washed Microbiota Transplantation for Attention-deficit\u002FHyperactivity Disorder and Its Comorbidities","Inclusion Criteria:\n\n1. Children with an established diagnosis of ADHD according to Diagnostic And Statistical Manual Of Mental Disorders Fifth Edition;\n2. Aged 3-17;\n3. Received stable treatments for ≥1 month preceding WMT;\n4. Did not take medications affecting gut microbiota such as antibiotics and probiotics three months before WMT.\n\nExclusion Criteria:\n\n1. Unable to understand the questionnaires or provide informed consent by the guardian;\n2. Diagnosed with a single-gene disorder, psychosis, central nervous system diseases, gastrointestinal diseases including ulcerative colitis, Crohn's disease, celiac disease, or eosinophilic esophagitis;\n3. Had severe comorbidities including cardiopulmonary failure, severe liver, and kidney diseases and cancer;\n4. Accompanied with other life-threatening disorders required emergency treatment;\n5. Unable to tolerate colonoscopy or anesthesia",true,"3 Years","17 Years",{"count":112,"type":21},50,[58],"Attention-deficit\u002Fhyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and hyperactivity-impulsivity. ADHD is often accompanied by oppositional defiant disorder and sleep disturbance, and can increase the risk of other psychiatric disorders, functional impairment in academic and occupational performance. Recently, gut microbiota has been implicated in the ADHD via gut-brain axis. In this study, investigators aimed to evaluate the efficacy of WMT for core ADHD symptoms and its comorbidities using specialized questionnaires for ADHD and investigate the underlying mechanism.",[116],"Attention-deficit\u002FHyperactivity Disorder",[118,89,91,119,120],"attention-deficit\u002Fhyperactivity disorder","sleep disturbance","gut-brain axis","2025-09-03",{"date":123,"type":39},"2025-09-05",{"date":125,"type":39},"2024-04-28",{"date":127,"type":21},"2027-07-01",{"name":45,"class":46},2,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100542234","washed-microbiota-transplantation-for-diabetic-gastroparesis-100542234","NCT06340217","Washed Microbiota Transplantation for Diabetic Gastroparesis","The Efficacy and Safety of WMT in the Treatment of Diabetic Gastroparesis: A Multicenter, Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Diagnosed with diabetes for over 1 year;\n2. Accompanied by symptoms such as abdominal bloating, early satiety, persisting for at least 3 months, with a GCSI Total Score greater than\u002Fequal to 2.3;\n3. Objective evidence of delayed gastric emptying within the past 3 months, including but not limited to scintigraphic gastric emptying or gastric ultrasound;\n4. Upper gastrointestinal obstructive lesions were ruled out by imaging or endoscopic examination within the past 3 months;\n5. Males and nonpregnant, non-breastfeeding females who are aged more than 18 years and sign the informed consent form;\n6. The subject or his\u002Fher legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\nSubjects who:\n\n1. Have any upper gastrointestinal pathology other than diabetic gastroparesis that would require therapy other than that provided in this trial;\n2. Have a prior history of gastric surgery, including but not limited to gastric bypass, gastrectomy, gastric banding, pyloroplasty, fundoplication, or vagotomy in past 1 year;\n3. Have any organic\u002Fneurological disease that is suspected to be causing gastroparesis, other than diabetes;\n4. Have been using medications affecting gastrointestinal motility, such as GLP-1 agonists;\n5. Have contraindications for intestinal tubing;\n6. Have a history of medication that regulate intestinal microbiome in last 48 hours;\n7. Have serious diabetic complications need immediately be dealt, such as diabetic ketoacidosis\n8. Have poor lung function and those deemed by the investigator to be affected by the study treatment, such as during COPD exacerbations;\n9. Have any of the following abnormalities in cardiac function and cardiac performance:\n\n   * Cardiac function rating≥Ⅲ according to New York Heart Association (NYHA);\n   * New myocardial infarction or unstable angina pectoris within 6 months;\n   * Electrocardiogram indicated prolonged QTc interval (male QTc≥450ms, female QTc≥470ms);\n   * requiring drug intervention (more than Ⅱ atrioventricular block).\n10. Have preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points);\n11. Kidney disease with KDIGO stage 3b (GFR\\\u003C45 ml\u002Fmin\u002F1.73m2) or above;\n12. Have infectious diseases such as active hepatitis (requiring long-term use of drugs), HIV or active tuberculosis;\n13. Have a history of drug abuse, alcoholism (defined as consuming more than 14 units per week, with 1 unit equivalent to 360 mL of beer, 45 mL of 40% alcohol, or 150 mL of wine), or substance misuse;\n14. Other significant systemic illnesses, such as malignant tumors;\n15. Have other situations in which the investigator deems it inappropriate to participate in this study.","100 Years",{"count":139,"type":21},46,[24],"This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients.",[143],"Diabetic Gastroparesis",[89,145,146,147,148],"diabetic gastroparesis","randomized controlled trial","transendoscopic enteral tube","microbiota medicine",{"date":150,"type":39},"2025-09-10",{"date":152,"type":39},"2024-04-01",{"date":154,"type":21},"2029-07",{"name":45,"class":46},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":137,"enrollmentInfo":163,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":47},"100535806","washed-microbiota-transplantation-for-type-1-diabetes-mellitus-100535806","NCT06256614","Washed Microbiota Transplantation for Type 1 Diabetes Mellitus","Washed Microbiota Transplantation for Type 1 Diabetes Mellitus: a Real World Research","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. At the time of informed consent, male or non-pregnant or non-lactating female.\n2. The diagnostic criteria for T1DM are confirmed by previous medical record.\n3. The subject or his\u002Fher legal representative gives informed consent, fully nderstands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\n1. Diagnosed as any type of diabetes other than type 1 diabetes mellitus;\n2. Subjects with severe life-threatening complications diabetes (such as ketoacidosis, or acute coronary syndrome, etc.);\n3. At the time of screening, the subject or his\u002Fher legal representative refuses to take effective contraception within 3 months after the last treatment.\n4. According to the judgment of the investigator, the subjects are not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subjects.",{"count":112,"type":21},"This is a real-world study to explore the safety and the efficacy of washed microbiota transplantation (WMT) for patients with Type 1 Diabetes Mellitus (T1DM).",[166],"Type 1 Diabetes",[89,168,169,170,171,172],"type 1 diabetes mellitus","glycemic variability","daily insulin dosage","hypoglycemia","insulin sensitivity",{"date":150,"type":39},{"date":175,"type":39},"2024-03-01",{"date":154,"type":21},{"name":45,"class":46},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":129},"100518454","phase-1-wmt-for-autism-spectrum-disorder-asd-100518454","NCT06030752","WMT for Autism Spectrum Disorder (ASD)","Washed Microbiota Transplantation (WMT) for Autism Spectrum Disorder (ASD)","Inclusion Criteria:\n\n* Children and adolescents with an established diagnosis of ADHD or ADHD + ASD according to the Diagnostic and Statistical Manual Of Mental Disorders Fifth Edition;.\n* Age 3-17 years.\n* Received stable treatments for ≥1 month preceding WMT\n\nExclusion Criteria:\n\n* Their guardian could not understand the questionnaires or provide informed consent.\n* Diagnosed with a single-gene disorder, major brain malformations, gastrointestinal diseases (ulcerative colitis, Crohn's disease, or eosinophilic esophagitis)\n* Had severe comorbidities including cardiopulmonary failure, severe liver, and kidney diseases, severe infection, tumors, etc.\n* Accompanied with other life-threatening disorders required emergency treatment.\n* Unable to tolerate colonoscopy or anesthesia.",{"count":186,"type":21},80,[58],"Autism Spectrum Disorder (ASD) is a group of serious neurodevelopmental disorders. A significant comorbidity exists between ADHD and ASD: 30%-50% of individuals with ASD exhibit ADHD symptoms, and two-thirds with ADHD show ASD traits. Intestinal microbial disturbance is common in children with ASD. A great deal of evidence shows that intestinal microbes can influence the brain to play its role through \"gut-brain-microbiota axis\". We intend to explore the role of Washed Microbiota Transplantation in improving symptoms of children in ASD with or without ADHD; To study the potential etiological mechanism of WMT for the neurodevelopmental disorders.",[190],"Autism Spectrum Disorder",[192,193,194,195],"fecal Microbiota Transplantation","Autism spectrum disorder","Gut microbiota","Gut-brain axis",{"date":123,"type":39},{"date":198,"type":39},"2023-09-20",{"date":200,"type":21},"2027-05-01",{"name":45,"class":46},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100550449","washed-microbiota-transplantation-for-malnutrition-100550449","NCT06447220","Washed Microbiota Transplantation for Malnutrition","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Meet any of the following two conditions: ①weight loss (\\>5% weight loss in the past 6 months or \\>10% weight loss in more than 6 months); ②low BMI (\\\u003C70 years old and BMI\\\u003C18.5kg\u002Fm2 or ≥70 years old and BMI\\\u003C22kg\u002Fm2);\n3. Underwent washed microbiota transplantation.\n\nExclusion Criteria:\n\n1. Expected survival time \\\u003C3 months;\n2. Women who are pregnant or breastfeeding;\n3. Other patients deemed not suitable for enrollment by the investigator.",{"count":82,"type":21},"Malnutrition is a pathological condition in which dietary intake fails to meet the body's energetic or nutritional needs. It may be caused by macronutrient or micronutrient deficiencies, high energy expenditure, impaired nutrient absorption or assimilation. Malnutrition can affect all stages of life. In adults, malnutrition is strongly associated with poor clinical outcomes such as increased morbidity, increased mortality and prolonged hospitalization. In children, malnutrition can lead to growth retardation, cognitive impairment and immune dysfunction.",[211],"Malnutrition",[89,213,91],"malnutrition","2025-07-06",{"date":216,"type":39},"2025-07-10",{"date":218,"type":39},"2023-12-17",{"date":220,"type":21},"2031-04",{"name":45,"class":46},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":47},"100472995","washed-microbiota-transplantation-for-malnutrition-after-nonphysiological-reconstruction-of-the-upper-gastrointestinal-tract-100472995","NCT05439135","Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract","An Open-label, Multicenter, Randomized Clinical Trial for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract: Washed Microbiota Transplantation Via Mid-gut Tube Versus Colonic Transendoscopic Enteral Tube","Inclusion Criteria:\n\n* Patients undergone nonphysiological reconstruction of the gastrointestinal tract (such as Billroth-II, Roux-en-Y, Child, Whipple reconstruction)\n* Aged over 18 years old;\n* Malnutrition is assessed by Nutritional Risk Screening 2002 score≥3 and Patient Generated Subjective Global Assessment (PG-SGA) score≥4;\n* Written informed consent;\n\nExclusion Criteria:\n\n* Expected survival time \\\u003C 3 months;\n* Still on anti-tumor therapy or it is expected during the visit;\n* Complicated with ascites or edema caused by malnutrition;\n* Known organic gastrointestinal disease (e.g., gastrointestinal infection, inflammatory bowel disease, or radiation enteritis);\n* Undergone other gastrointestinal surgery (e.g., enterectomy, enterostomy, or gastrostomy) except appendectomy or anal fistula surgery;\n* Complicated with contraindications of enteral nutrition such as ileus, active gastrointestinal bleeding, and shock;\n* Cannot tolerate gastroscopy or colonoscopy;\n* Severe comorbidities (e.g., diabetes, cardiopulmonary failure, severe liver or or kidney diseases);\n* Complicated with other wasting diseases (e.g., active tuberculosis, hyperthyroidism, diabetes, HIV, active hepatitis, hip fracture, craniocerebral injury, etc.);\n* A history of anti-infective treatment within 30 days before enrollment; or need anti-infective treatment at the time of enrollment; or unwilling to stop taking drugs that affect gut microbes, such as probiotics;\n* Can not tolerate oral enteral nutrition;\n* Women who are pregnant or breastfeeding;\n* Participating in another clinical trial;\n* Deemed unsuitable for inclusion by the investigators.",{"count":230,"type":21},62,[24],"This is a prospective, randomized, multicenter study to evaluate WMT in improving nutritional status in malnourished patients who underwent nonphysiological reconstruction of the upper gastrointestinal tract. In this multicenter trial, sixty-two patients will be enrolled in forteen Chinese sites. Participants will be randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic TET. After WMT, each participant will receive free diet plus home enteral nutrition. Home enteral nutrition should last for 2 months at home, with blood, urine and stool samples taken and stored at baseline and 2 months after WMT.",[211,234],"Gastroenterostomy",[89,236,213,237,238,239,240,241],"fecal microbiota transplant","enteral nutrition","cachexia","upper gastrointestinal rerouting surgery","delivery","nonphysiological reconstruction of the upper gastrointestinal tract",{"date":216,"type":39},{"date":244,"type":39},"2024-10-20",{"date":246,"type":21},"2025-10-31",{"name":45,"class":46},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":47},"100580041","phase-1-cmts4520-for-chronic-constipation-in-adults-100580041","NCT06832137","CMTS4520 for Chronic Constipation in Adults","The Efficacy and Safety of CMTS4520 for Chronic Constipation in Adults： A Randomized, Double-Blind, Placebo-Controlled Trial.","Inclusion Criteria:\n\n\\-\n\nMeet all of the following inclusion criteria :\n\n1. Voluntary sign informed consent, age 18-70 years old (including the threshold), male and female.\n2. For subjects diagnosed with chronic constipation, the duration of the disease is at least 6 months, and meet the following criteria:\n\n   1. Frequency of spontaneous defecation \\\u003C3 times\u002Fweek (spontaneous defecation refers to spontaneous defecation without the aid of remedial purgatives or manual assistance).\n   2. Dry and hard stool: More than a quarter of the stool is type 1 or 2 on the Bristol Fecal Trait Scale.\n3. The subject or his\u002Fher legal representative has given informed consent, is fully aware of the purpose of the study, is able to communicate well with the investigator, and is able to understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n\\-\n\nAll exclusion criteria below are not met:\n\n1. Participants with outlet obstruction constipation, such as rectal mucosal prolapse.\n2. Participants with a history of intestinal resection.\n3. Participants with intestinal stenosis caused by organic lesions of the digestive tract (e.g., tumor, inflammation, anal fissures, Crohn's disease, ulcerative colitis, radiation enteritis, intestinal adhesions, intestinal tuberculosis) as confirmed by colonoscopy within the past 24 months.\n4. Participants with constipation secondary to systemic diseases affecting the digestive tract, including:\n\n   1. Neurological diseases (e.g., Parkinson's disease, spinal cord injury, multiple sclerosis).\n   2. Muscle diseases (e.g., amyloidosis, dermatomyositis).\n   3. Psychiatric disorders or severe mood disorders (e.g., A Hospital Anxiety and Depression Scale score ≥15).\n   4. Opioid-induced constipation.\n   5. Poorly controlled metabolic diseases (e.g., thyroid dysfunction) or metabolic diseases with gastrointestinal complications (e.g., gastrointestinal autonomic dysfunction, diabetic gastroparesis).\n5. Have a history of major surgery or severe trauma within 3 months and have not fully recovered.\n6. Participants with any of the following cardiac abnormalities:\n\n   1. New York Heart Association (NYHA) Class III or higher heart failure.\n   2. Myocardial infarction or unstable angina within the past 6 months.\n   3. Prolonged QTc interval on electrocardiogram (≥450ms for males, ≥470ms for females).\n   4. Atrial arrhythmias that cannot be stably controlled by drugs and ventricular arrhythmias requiring pharmacological control (including grade 2 or higher atrioventricular block).\n7. Participants with poor lung function, as assessed by the investigator, that may impact study treatment, such as acute chronic obstructive pulmonary disease(COPD) or those requring long-term oral, intravenous corticosteroids (excluding inhalant\u002Fspray formulations).\n8. Uncontrolled immune diseases requring long-term systemic corticosteroid use (excluding topical use).\n9. Participants with reproductive system disorders that may cause abdominal pain (e.g., ovarian cysts, endometriosis, primary dysmenorrhea).\n10. Participants with significant laboratory abnormalities that, in the investigator's judgment, may affect safety or study completion, including:\n\n    1. Hemoglobin \\\u003C100g\u002FL.\n    2. Serum creatinine ≥1.5 times the upper limit of normal (ULN).\n    3. Abnormal liver function (AST\\>1.5×ULN, ALT\\>1.5×ULN or total bilirubin \\>1.5×ULN).\n    4. Clinically significant abnormalitieshe in routine stool tests or fecal occult blood indicating gastrointestinal lesions.\n11. Participants with active hepatitis (requiring or undergoing long-term treatment), HIV, or active tuberculosis.\n12. Participants with a history of drug or alcohol abuse (defined as consuming more than 14 standard drinks peer week: 1 standard drink= 360mL of beer, 45mL of 40% spirits, or 150mL of wine) or substance abuse.\n13. Participants with known allergies or intolerances to the investigational drug, similar drugs or excipients.\n14. Participants who have used anti-infective drugs (antibiotics, antifungals, antivirals) within 14 days prior to enrollment or require anti-infective treatment at the time of enrollment evaluation.\n15. Participants who have used drugs or foods that regulate intestinal microbiota (e.g., bifidobacterium, probiotics, prebiotics, fermented milk, yogurt) within 2 weeks prior to screening or during the study.\n16. Participants who have undergone hydrotherapy for bowel cleansing within one month prior to treatment.\n17. Women who are pregnant, breastfeeding, or unwilling to use effective contraception for 3 months after the last dose of the study drug.\n18. Participants who have participated in drug intervention clinical trials within 1 month prior to enrollment.\n19. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","70 Years",{"count":82,"type":21},[58,59],"This is a randomized controlled trial to explore the efficacy and safety of CMTS4520 (Dietary Fiber Probiotics) for patients with chronic constipation.",[260],"Constipation",[262,263,146,264,265],"CMTS4520","constipation","dietary fiber","probiotics","NOT_YET_RECRUITING","2025-03-30",{"date":269,"type":39},"2025-04-03",{"date":271,"type":21},"2025-03-31",{"date":273,"type":21},"2030-06-01",{"name":45,"class":46},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":47},"100325395","fecal-microbiota-transplantation-for-radiation-enteritis-100325395","NCT03516461","Fecal Microbiota Transplantation for Radiation Enteritis","Efficacy and Safety of Fecal Microbiota Transplantation in Radiation Enteritis","Inclusion Criteria:\n\n1. age ≥18 years old;\n2. Radiation enteritis diagnosed by colonoscopy after finishing radiotherapy.\n\nExclusion Criteria:\n\n1. Patients who were pregnant or nursing;\n2. Patients who were unable or unwilling to undergo a gastroscopy;\n3. Patients who had gastrointestinal infection;\n4. Patients with cardiopulmonary failure.","85 Years",{"count":284,"type":21},70,[24],"Radiation enteritis is one of the most feared complications after abdominal or pelvic radiation therapy.The gut microbiota is considered to constitute a \"microbial organ\" which has pivotal roles in the intestinal diseases and body metabolism. Evidence from animal studies demonstrated the link between intestinal bacteria and radiation enteritis. This clinical trial aims to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) for radiation enteritis.",[288],"Radiation Enteritis",[290,288,291],"Gut Microbiota","Fecal Microbiota Transplantation","2025-03-27",{"date":267,"type":39},{"date":295,"type":39},"2018-01-07",{"date":297,"type":21},"2025-07-01",{"name":45,"class":46},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":47},"100417848","washed-microbiota-transplantation-for-the-treatment-of-oncotherapy-related-intestinal-complications-100417848","NCT04721041","Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications","Efficacy and Safety of Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications","Inclusion Criteria:\n\n* 1\\. Age ≥18 years old; 2. Diagnosed as malignant tumor; 3. Patients who underwent cancer-related treatment suffering from gastrointestinal symptoms(e.g., abdominal pain, diarrhea, abdominal distension, and difficulty defecating) occurred after standard tumor therapy (such as chemotherapy, radiation, immunotherapy, surgical treatment, etc.); 4. Estimated time of survival ≥ 3 months, and vital signs were stable); 5. Physically qualified and intended to undergo FMT;\n\nExclusion Criteria:\n\n* 1\\. Patients who were pregnant or nursing; 2. Patients who were unable or unwilling to undergo a gastroscopy or colonoscopy; 3. Patients with cardiopulmonary failure; 4. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the previous week; 5. history of inflammatory bowel disease and intestinal symptoms unrelated to tumor treatment; 6.Serious uncontrolled diseases and acute infectious diseases；",{"count":307,"type":21},200,[24],"Gut microbiota, known as \"unrecognized organs\", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. The investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.",[311,312],"Intestinal Complications","Cancer",[291,314,315,312,316],"Washed Microbiota Transplantation","Oncotherapy","Intestinal dysbiosis","2025-03-03",{"date":71,"type":39},{"date":320,"type":39},"2021-01-26",{"date":322,"type":21},"2025-05",{"name":45,"class":46},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":47},"100580615","phase-1-cmts4520-assisted-washed-microbiota-transplantation-for-chronic-diarrhoea-in-adults-100580615","NCT06839599","CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults","The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults： a Randomized, Double-Blind, Placebo-Controlled Trial.","Inclusion Criteria:\n\nMeet all of the following inclusion criteria :\n\n1. Voluntary sign informed consent, age 18-70 years old (including the threshold), male and female.\n2. Using the Rome IV criteria as the diagnostic criteria:\n\n   1. Defecation frequency is greater than or equal to 3 times per day or significantly exceeds the usual habit, with a disease duration of \\> 4 weeks, or recurrent diarrhea with an intermittent period within 2 - 4 weeks;\n   2. Loose stools: Types 5, 6, and 7 based on the Bristol Stool Form Scale.\n3. The subject or his\u002Fher legal representative has given informed consent, is fully aware of the purpose of the study, is able to communicate well with the investigator, and is able to understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\nAll exclusion criteria below are not met:\n\n1. Participants with a history of intestinal resection.\n2. Participants with organic lesions of the digestive tract (e.g., tumor, inflammation, anal fissures, Crohn's disease, ulcerative colitis, radiation enteritis, intestinal adhesions, intestinal tuberculosis) as confirmed by colonoscopy within the past 24 months.\n3. Participants with diarrhoea secondary to systemic diseases affecting the digestive tract, including:\n\n   1. Neurological diseases (e.g., Parkinson's disease, spinal cord injury, multiple sclerosis).\n   2. Muscle diseases (e.g., amyloidosis, dermatomyositis).\n   3. Psychiatric disorders or severe mood disorders (e.g., A Hospital Anxiety and Depression Scale score ≥15).\n   4. Opioid-induced diarrhoea.\n   5. Poorly controlled metabolic diseases (e.g., thyroid dysfunction) or metabolic diseases with gastrointestinal complications (e.g., gastrointestinal autonomic dysfunction, diabetic gastroparesis).\n4. Diarrhea secondary to intestinal infectious diseases, including but not limited to Clostridioides difficile infection, chronic bacillary dysentery, intestinal tuberculosis, and parasitic infection-induced diarrhea.\n5. Have a history of major surgery or severe trauma within 3 months and have not fully recovered.\n6. Participants with any of the following cardiac abnormalities:\n\n   1. New York Heart Association (NYHA) Class III or higher heart failure.\n   2. Myocardial infarction or unstable angina within the past 6 months.\n   3. Prolonged QTc interval on electrocardiogram (≥450ms for males, ≥470ms for females).\n   4. Atrial arrhythmias that cannot be stably controlled by drugs and ventricular arrhythmias requiring pharmacological control (including grade 2 or higher atrioventricular block).\n7. Participants with poor lung function, as assessed by the investigator, that may impact study treatment, such as acute chronic obstructive pulmonary disease(COPD) or those requring long-term oral, intravenous corticosteroids (excluding inhalant\u002Fspray formulations).\n8. Uncontrolled immune diseases requring long-term systemic corticosteroid use (excluding topical use).\n9. Participants with reproductive system disorders that may cause abdominal pain (e.g., ovarian cysts, endometriosis, primary dysmenorrhea).\n10. Participants with significant laboratory abnormalities that, in the investigator's judgment, may affect safety or study completion, including:\n\n    1. Hemoglobin \\\u003C100g\u002FL.\n    2. Serum creatinine ≥1.5 times the upper limit of normal (ULN).\n    3. Abnormal liver function (AST\\>1.5×ULN, ALT\\>1.5×ULN or total bilirubin \\>1.5×ULN).\n    4. Clinically significant abnormalitieshe in routine stool tests or fecal occult blood indicating gastrointestinal lesions.\n11. Participants with active hepatitis (requiring or undergoing long-term treatment), HIV, or active tuberculosis.\n12. Participants with a history of drug or alcohol abuse (defined as consuming more than 14 standard drinks peer week: 1 standard drink= 360mL of beer, 45mL of 40% spirits, or 150mL of wine) or substance abuse.\n13. Participants with known allergies or intolerances to the investigational drug, similar drugs or excipients.\n14. Participants who have used anti-infective drugs (antibiotics, antifungals, antivirals) within 14 days prior to enrollment or require anti-infective treatment at the time of enrollment evaluation.\n15. Participants who have used drugs or foods that regulate gut microbiota (e.g., bifidobacterium, probiotics, prebiotics, fermented milk, yogurt) within 2 weeks prior to screening or during the study.\n16. Women who are pregnant, breastfeeding, or unwilling to use effective contraception for 3 months after the last dose of the study drug.\n17. Participants who have participated in drug intervention clinical trials within 1 month prior to enrollment.\n18. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":82,"type":21},[58,59],"This is a randomized controlled trial to explore the efficacy and safety of CMTS4520 (Dietary Fiber Probiotics) assisted washed microbiota transplantation for patients with chronic diarhoea.",[335],"Diarrhea",[89,337,262,338,264,265],"diarrhea","randomized controlled study","2025-02-20",{"date":341,"type":39},"2025-02-21",{"date":339,"type":21},{"date":344,"type":21},"2030-07-01",{"name":45,"class":46},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":370,"locationsCount":47},"100580371","early-phase-1-cmts0929-for-clostridioides-difficile-infection-100580371","NCT06836427","CMTS0929 for Clostridioides Difficile Infection","CMTS0929 for Clostridioides Difficile Infection: a Prospective, Open-label, Single-arm Clinical Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. At the time of informed consent, the age is between 18 and 75 years old (inclusive), including both males and non - pregnant, non - lactating females.\n2. At the time of screening, meet the diagnostic criteria for Clostridioides difficile infection: a)There is a medical record proving a confirmed CDI before screening (laboratory tests show positive results for Clostridioides difficile or its toxins): positive results in Clostridioides difficile toxin detection (determined by EIAs) or colonoscopy indicating pseudomembranous colitis; or positive GDH with negative toxin results, along with obvious predisposing factors and diarrhea. b)Have an episode of CDI - related diarrhea, that is, having at least 3 bowel movements per day for at least two consecutive days and the stools are unformed (Bristol Stool Form Scale score of 6 - 7).\n3. The subject or their legal representative provides informed consent, fully understands the purpose of the study, can communicate well with the researcher, and can understand and comply with all the requirements of this study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\n1. Subjects with immunodeficiency (such as HIV infection, or absolute neutrophil count \\\u003C 0.5×10⁹\u002FL, or total lymphocyte count \\\u003C 0.5×10⁹\u002FL, etc.), or those using immunosuppressants, or those using medium - to high - dose steroid hormones (≥20 g\u002Fd prednisone or equivalent steroid hormones).\n2. Subjects with rectal outlet obstruction (such as rectal mucosal prolapse) or significant intestinal stenosis that, as evaluated by the researcher, cannot undergo cTET.\n3. Before screening, subjects are diagnosed or clinically suspected of having an infection with other pathogenic microorganisms in addition to Clostridioides difficile.\n4. Within 6 months before screening, subjects have undergone major abdominal surgery (excluding laparoscopic cholecystectomy or appendectomy), or have previously undergone partial or total colectomy, or partial small intestine resection, or gastroduodenal surgery.\n5. At the time of screening, the subject or legal representative refuses to use effective contraceptive measures within 3 months after the last treatment.\n6. As judged by the researcher, the subject is not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subject.","75 Years",{"count":355,"type":21},12,[357],"EARLY_PHASE1","This is a prospective, open-label, single-arm study to explore the safety and the efficacy of CMTS0929 for patients with Clostridioides difficile infection (CDI).",[360],"Clostridioides Difficile Infection",[362,363,364,365],"CMTS0929","Clostridioides difficile infection","efficacy","safety","2025-02-19",{"date":339,"type":39},{"date":339,"type":21},{"date":344,"type":21},{"name":45,"class":46},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":353,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":389,"locationsCount":47},"100581007","early-phase-1-cmts0929-for-inflammatory-bowel-disease-100581007","NCT06844708","CMTS0929 for Inflammatory Bowel Disease","CMTS0929 for Inflammatory Bowel Disease: a Prospective, Open-label, Single-arm Clinical Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Patients diagnosed with inflammatory bowel disease (IBD) based on typical clinical symptoms, endoscopic findings, and histological criteria.\n2. Aged between 18 and 75 years old, regardless of gender.\n3. No history of using antibiotics, prebiotics, or probiotics within at least the past month.\n4. Patients who can fully understand the content of the informed consent form for this trial and voluntarily sign the written informed consent.\n5. Patients willing to undergo subsequent follow - up and comply with other requirements of the protocol.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\n1. Women who are pregnant or plan to become pregnant during the trial.\n2. Patients who have any doubts about this technology or have a history of other risks.\n3. Patients in the terminal stage of the disease or who may die during the study.\n4. Patients with a history of antibiotic use within three months before transplantation or who have participated in other clinical trials.\n5. Patients who have participated in any other microbiota - based therapies before enrollment.\n6. Patients with positive antibodies for hepatitis B, tuberculosis, syphilis, or HIV, or those in the acute phase of any infectious disease.\n7. Patients with cardiac function at grade III or higher, elevated transaminases more than twice the upper limit of the normal range, or renal insufficiency (glomerular filtration rate (GFR) less than 60 ml\u002Fmin).\n8. Patients with a fever of over 38 °C or clinically obvious active infections that may affect this trial.\n9. Patients with severe anemia (hemoglobin \\\u003C 60 g\u002FL), granulocytopenia (absolute neutrophil count \\\u003C 1.5×10⁹\u002FL), or prolonged prothrombin time (PT) by more than 1.5 seconds.\n10. Patients with obvious cardiovascular and cerebrovascular abnormalities (such as tachycardia or uncontrolled atrial fibrillation, acute coronary syndrome, stroke, or recurrent transient ischemic attacks (TIAs)); a history of arrhythmia (multifocal ventricular premature beats, bigeminy, trigeminy, congenital long QT syndrome), or patients with heart diseases that, in the judgment of the researcher, increase the risk of ventricular arrhythmia.\n11. Situations identified by the researcher during the trial that may affect the patient's compliance and\u002For the completion of trial - related procedures, or clinical contraindications related to the pre - trial.\n12. Patients who have undergone abdominal organ surgery within three months before treatment, patients less than 6 weeks after major organ surgery, or patients with poor wound healing after surgery.\n13. Patients with gastrointestinal obstructive diseases, tumors, or hepatic or renal insufficiency.\n14. Pregnant or lactating women, or women with the intention of becoming pregnant.\n15. Patients suspected or confirmed to be drug users, or those with a history of immunodeficiency (such as positive HIV antibodies or currently receiving immunosuppressive therapy).\n16. Patients with known major active infections, or those with major disorders in blood, renal, metabolic, gastrointestinal, or endocrine functions as judged by the researcher.\n17. Other situations deemed unsuitable for enrollment by the researcher.",{"count":355,"type":21},[357],"This is a prospective, open-label, single-arm study to explore the safety and the efficacy of China Microbiota Transplantation System 0929 (CMTS0929) for patients with inflammatory bowel disease (IBD).",[382],"Inflammatory Bowel Disease (IBD)",[384,362,364,365],"inflammatory bowel disease",{"date":386,"type":39},"2025-02-25",{"date":339,"type":21},{"date":344,"type":21},{"name":45,"class":46},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":397,"targetDuration":399,"studyType":84,"phases":4,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":47},"100580430","washed-microbiota-transplantation-combined-with-enteral-nutrition-for-gastroptosis-100580430","NCT06837194","Washed Microbiota Transplantation Combined With Enteral Nutrition for Gastroptosis","The Efficacy of WMT Combined With Nutritional Support in the Treatment of Malnutrition Complicated by Gastroptosis: A Real-World Study","Inclusion Criteria:\n\n* Subjects must meet all of the following inclusion criteria to enter the study:\n\n  1. Clinically diagnosed with gastroptosis;\n  2. Meets the diagnostic criteria for malnutrition (fulfilling any one of the following two criteria):\n\n     * Weight loss (weight loss \\>5% within the last 6 months or \\>10% over more than 6 months);\n\n       * Low BMI (BMI \\\u003C18.5 kg\u002Fm² for individuals \\\u003C70 years old; BMI \\\u003C20 kg\u002Fm² for individuals ≥70 years old);\n  3. Males aged ≥18 years and non-pregnant, non-lactating females aged ≥18 years;\n  4. Willing to voluntarily sign a written informed consent form and agrees to follow medical advice for regular follow-up examinations and monitoring after the completion of treatment.\n\nExclusion Criteria:\n\n* Subjects meeting any of the following exclusion criteria must be excluded from the study:\n\n  1. Patients with severe depression, anxiety, or cognitive impairment that affects normal physician-patient communication and treatment planning;\n  2. Patients with poor compliance who cannot accept treatment regimens such as nasogastric enteral nutrition;\n  3. Anticipated survival time \\\u003C3 months;\n  4. Clinically significant cardiovascular diseases, including heart failure (NYHA Class III-IV), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, history of myocardial infarction, hemodynamic instability at enrollment, unstable vital signs, or anticipated risk events during treatment;\n  5. Poor pulmonary function deemed by investigators to impact study treatment (e.g., acute exacerbation of COPD or requirement for long-term oral\u002Fintravenous corticosteroids \\[excluding inhaled corticosteroids\\]);\n  6. Active severe clinical infections (\\> Grade 2 per NCI-CTCAE v5.0), including patients with intestinal fungal, viral, or tuberculosis infections;\n  7. Inability to cooperate with intestinal tube placement or contraindications to intestinal tube placement;\n  8. Use of medications affecting or modulating gut microbiota within the past 48 hours;\n  9. Lack of legal capacity or restricted legal capacity;\n  10. Hematologic disorders unsuitable for blood draw examinations;\n  11. Other severe medical conditions deemed by investigators to preclude patient enrollment.",{"count":398,"type":21},24,"24 Years","This is a observational study to explore the efficacy and safety of washed microbiota transplantation (WMT) combined with nutritional support for gastroptosis patients",[402,211],"Gastroptosis",[89,148,402,213,237,404],"Transendoscopic Enteral Tubing","2025-02-15",{"date":339,"type":39},{"date":408,"type":39},"2025-02-01",{"date":127,"type":21},{"name":45,"class":46},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":418,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":427,"locationsCount":47},"100580044","phase-1-cmts4520-assisted-washed-microbiota-transplantation-for-chronic-constipation-in-adults-100580044","NCT06832176","CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in Adults","The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in Adults： a Randomized, Double-Blind, Placebo-Controlled Trial.",{"count":82,"type":21},[58,59],"This is a randomized controlled trial to explore the efficacy and safety of CMTS4520 (Dietary Fiber Probiotics) assisted washed microbiota transplantation for patients with chronic constipation.",[260],[89,263,262,146,264,265],"2025-02-12",{"date":424,"type":39},"2025-02-18",{"date":339,"type":21},{"date":344,"type":21},{"name":45,"class":46},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":47},"100572221","microbiota-transplantation-in-solid-organ-transplantation-100572221","NCT06730451","Microbiota Transplantation in Solid Organ Transplantation","Washed Microbiota Transplantation for Postoperative Complications in Solid Organ Transplantation","Inclusion Criteria:\n\n1. solid organ transplantation recipients;\n2. suffering from gastrointestinal symptoms (e.g. diarrhea, constipation, abdominal pian), infection (e.g. Clostridium difficile) post-transplantation and so on;\n3. is willing to undergo WMT and provide written informed consent.\n\nExclusion Criteria:\n\n1. patients with history of gastrointestinal diseases or homologous pathogen infection pre-transplant;\n2. pregnant or lactating females;\n3. expected survival\\\u003C1 months;\n4. unable to understand the purpose of the study, communicate effectively with investigators and comply with all study procedures;\n5. follow up less than 1-month post-WMT;\n6. other conditions judged by investigators not suitable for study participation.",{"count":112,"type":21},"Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life. Posttransplant complications such as gastrointestinal symptoms, infection, and graft rejection increase risk with graft failure and death. However, the treatment of abovementioned complications remains unsatisfactory. Gut dysbiosis has been reported in patients with SOT, especially in patients with posttransplant complications. Recipients are more susceptible to gut dysbiosis as long-term use of immunosuppressants, antibiotics and corticosteroids. Restoring gut microbiome may be a promising therapy for posttransplant complications. Washed microbiota transplantation (WMT) is a newly improved methodology of fecal microbiota transplantation based on automatic facilities, washing process and a new delivery routine. In this study, investigators aimed to evaluate the efficacy and safety of WMT for postoperative complications in SOT.",[438],"Solid Organ Transplant Complications",[438,440,441,335],"Washed microbiota transplantation","Fecal microbiota transplantation","2024-12-11",{"date":444,"type":39},"2024-12-12",{"date":446,"type":39},"2018-01-01",{"date":448,"type":21},"2028-12-31",{"name":45,"class":46},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":129},"100193428","standardized-fecal-microbiota-transplantation-for-crohnaposs-diseases-100193428","NCT01793831","Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases","Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases","Inclusion Criteria:\n\nClinical diagnosis of Crohn's disease, with the diagnosis remaining unchanged after at least three months of follow-up.\n\nWillingness to undergo FMT (Fecal Microbiota Transplantation).\n\nExclusion Criteria:\n\nPresence of serious conditions that made them unsuitable for inclusion (e.g., malignant neoplasms, cardiopulmonary failure, serious liver or kidney disease).",{"count":458,"type":21},800,[24],"The gut microbiota is considered to constitute a \"microbial organ\" which has pivotal roles in the intestinal diseases and body's metabolism. Evidence from animal and human studies strongly supports the link between intestinal bacteria and inflammatory bowel diseases (IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile colitis. Preliminary studies using fecal microbiota transplantation (FMT) for Ulcerative Colitis (UC), Crohn's diseases (CD), irritable bowel syndrome (IBS) and constipation have also met with some success. However, the results on CD is very limited. This marks the initial step in exploring the potential efficacy of fecal bacteriotherapy for CD. The investigators aim to evaluate the effectiveness, durability, and safety of FMT in a cohort of at least 500 patients with CD over a ten-year period",[462,463],"Inflammatory Bowel Disease","Crohn's Disease (CD)",[465,466,467,441,468],"Inflammatory bowel disease","Fecal transplantation","Fecal bacteriotherapy","Crohn's disease","2024-11-26",{"date":471,"type":39},"2024-11-29",{"date":473,"type":39},"2013-02",{"date":475,"type":21},"2025-12",{"name":45,"class":46},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":433,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":436,"conditions":485,"keywords":486,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":47},"100570548","washed-microbiota-transplantation-in-solid-organ-transplantation-100570548","NCT06708676","Washed Microbiota Transplantation in Solid Organ Transplantation","Inclusion Criteria:\n\n1. solid organ transplantation recipients;\n2. suffering from gastrointestinal symptoms (e.g. diarrhea, constipation, abdominal pian), infection (e.g. Clostridium difficile, urinary infection) post-transplantation, graft rejection and so on;\n3. is willing to undergo WMT and provide written informed consent;\n\nExclusion Criteria:\n\n1. patients with history of gastrointestinal diseases or homologous pathogen infection pre-transplant;\n2. pregnant or lactating females;\n3. unable to understand the purpose of the study, communicate effectively with investigators and comply with all study procedures;\n4. follow up less than 1-month post-WMT;\n5. other conditions judged by investigators not suitable for study participation;",{"count":112,"type":21},[24],[438],[438,440,441,335,487],"Clostridium difficile","2024-11-24",{"date":490,"type":39},"2024-11-27",{"date":492,"type":21},"2024-11-20",{"date":73,"type":21},{"name":45,"class":46},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":108,"sex":17,"minAge":503,"maxAge":110,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":129},"100344444","phase-1-washed-microbiota-transplantation-for-tourettes-syndrome-100344444","NCT03764748","Washed Microbiota Transplantation for Tourette's Syndrome","Efficacy and Safety of Washed Microbiota Transplantation for Tourette's Syndrome","WMT","Inclusion Criteria:\n\n1. Patients were aged 6 to 17 years (inclusive);\n2. Met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for TS;\n3. Had a Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) of at least 20 at screening and baseline.\n4. Underwent WMT.\n\nExclusion Criteria:\n\n1. Complicated with certain brain disease, including tumor,injury,cerebrovascular disease;\n2. Complicated with other severe disease, including cancers, organ failure, heart diseases;\n3. Stereotypy associated with autism spectrum disorder;\n4. With a confirmed diagnosis of psychiatric diseases, such as bipolar disorders; schizophrenia and major depressive disorders;\n5. Clinically significant obsessive-compulsive disorder at baseline considered to be the primary cause of impairment at baseline;\n6. Medications use affecting gut microbiota such as antibiotics and probiotics three months before WMT.\n7. Other neurologic disorders other than TS that could influence the evaluation of tics.","6 Years",{"count":505,"type":21},30,[58],"This study aimed to evaluate the efficacy of washed microbiota transplantation in the treatment of Tourette's syndrome (TS).",[509],"Tourette Syndrome",[511,194,512,314,513],"Tic Disorders","Brain-gut axis","Tourette syndrome","2024-08-15",{"date":516,"type":39},"2024-08-19",{"date":518,"type":39},"2024-04-17",{"date":520,"type":21},"2027-10-31",{"name":45,"class":46},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":47},"100553531","phase-2-iron-administration-via-colonic-tet-combined-with-wmt-for-id-100553531","NCT06487299","Iron Administration Via Colonic TET Combined With WMT for ID","Iron Administration Via Colonic Transendoscopic Enteral Tubing Combined With Washed Microbiota Transplantation for Iron Deficiency:A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n1. ferritin ≤30 μg\u002FL;\n2. feasible colonic TET placement (cephalic end in the ileocecal region);\n3. completion of 3 WMT sessions.\n\nExclusion Criteria:\n\n1. The patient has other co-morbidities that can lead to iron deficiency, such as acute gastrointestinal haemorrhage and menorrhagia.etc.\n2. People who are allergic to iron or taking oral medications that interfere with iron absorption.\n3. Patients with heart, brain, lung, liver, kidney and other serious diseases;\n4. Patients do not cooperate to complete the clinical trial process;",{"count":530,"type":21},60,[59],"The colon can absorb iron.We propose an integrated approach utilizing colonic transendoscopic enteral tubing to deliver iron in different valence states, coupled with washed microbiota transplantation . This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for the treatment of iron deficiency.",[534],"Iron Deficiency Anemia in Childbirth",[536,537,314,538],"Iron","Transendoscopic enteral tubing","iron deficiency","2024-07-19",{"date":541,"type":39},"2024-07-22",{"date":543,"type":21},"2024-07-25",{"date":36,"type":21},{"name":45,"class":46},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":353,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":47},"100545708","phase-2-fluorouracil-treatment-via-colon-for-colorectal-cancer-100545708","NCT06385418","Fluorouracil Treatment Via Colon for Colorectal Cancer","Fluorouracil Treatment Via Colon for Colorectal Cancer: an Exploratory Study","Inclusion Criteria:\n\n1. Chinese individuals aged 18 to 75 years, both male and female;\n2. Histologically confirmed diagnosis of colorectal cancer with measurable primary lesion according to RECIST 1.1;\n3. ECOG performance status ≤2;\n4. Expected survival of more than 3 months;\n5. Multidisciplinary team consensus that the patient is suitable for adding local chemotherapy to the established tumor treatment regimen;\n6. Adequate organ function meeting the following criteria: (1) Absolute neutrophil count ≥1.5 × 10\\^9\u002FL, platelets ≥100 × 10\\^9\u002FL, hemoglobin ≥90 g\u002FL; (2) Total bilirubin ≤1.5 times the upper limit of normal (patients with biliary drainage via retrograde techniques included); ALT and AST ≤5 times the upper limit of normal, and for patients with liver metastases, serum total bilirubin less than or equal to 3 times the upper limit of the normal reference range; (3) Creatinine \\\u003C120 μmol\u002FL, or MDRD estimated glomerular filtration rate \\>60 mL\u002Fmin; (4) Doppler echocardiography assessment: Left ventricular ejection fraction (LVEF) ≥50%;\n7. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days before enrollment, and sexually active men or women agree to use appropriate contraception during the trial and for 8 weeks after the last dose of investigational drug;\n8. Suitable physical condition and personal willingness to undergo colonic transendoscopic enteral tubing;\n9. Willingness to cooperate with physicians, and agree to regular follow-up visits and examinations as recommended after completion of treatment;\n10. Agreement to specimen collection and voluntary signing of a written informed consent form.\n\nExclusion Criteria:\n\n1. Uncontrolled cardiovascular diseases, such as congestive heart failure (NYHA III-IV), coronary artery disease, cardiomyopathy, arrhythmias, or hemodynamic instability at enrollment, with a risk of significant events during the treatment period;\n2. Active severe clinical infections (≥ Grade 2 according to NCI-CTCAE version 5.0), including fungal, viral, or tuberculosis infections within the gastrointestinal tract;\n3. Coagulation abnormalities with bleeding tendencies (who do not meet the criteria of having a normal INR without the use of anticoagulants within 14 days prior to enrollment). Participants receiving anticoagulants or vitamin K antagonists such as warfarin or heparin are excluded unless their international normalized ratio (INR) is ≤1.5, with allowance for low-dose warfarin (1 mg orally once daily) or low-dose aspirin (daily dose not exceeding 100 mg) for prophylaxis;\n4. History of immunodeficiency or other acquired or congenital immunodeficiency diseases, or history of organ transplantation;\n5. Known progressive or actively treated other malignancies requiring intervention, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ;\n6. Presence of other serious diseases that would render the subject ineligible for enrollment as determined by the investigator;\n7. Breastfeeding women;\n8. Known allergy or intolerance to the investigational drug or its excipients;\n9. Participation in another drug clinical trial within the past four weeks;\n10. Lack of legal capacity or restricted legal capacity.",{"count":554,"type":21},40,[59],"Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive hydrogel presents a promising carrier for 5-FU to address challenges encountered with traditional administration methods. We propose an integrated approach utilizing colonic transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for treating CRC.",[558],"Colorectal Cancer",[560,537,561,558],"Fluorouracil","Thermosensitive hydrogel","2024-06-25",{"date":564,"type":39},"2024-06-26",{"date":566,"type":39},"2024-05-16",{"date":568,"type":21},"2029-05-01",{"name":45,"class":46},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":47},"100548501","phase-2-effect-and-mechanism-of-baitouweng-decoction-for-large-intestine-damp-heat-syndrome-of-ulcerative-colitis-100548501","NCT06421818","Effect and Mechanism of Baitouweng Decoction for Large Intestine Damp-heat Syndrome of Ulcerative Colitis","Formula-to-Syndrome Effect and Pharmacomicrobiomics Mechanism of Colon Delivery of Baitouweng Decoction for Treating Large Intestine Damp-heat Syndrome of Ulcerative Colitis","Inclusion Criteria:\n\n1. Patients diagnosed with ulcerative colitis;\n2. The patients are in mild to moderate active stage with Mayo score of 3-8.\n3. Patients with damp-heat syndrome of large intestine according to TCM syndrome differentiation: according to the expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of UC, the main symptoms are diarrhea, mucopurulent and bloody stool, abdominal pain, and tenesmus. Secondary symptoms: anal burning, body heat is not Yang, dry mouth and bitter mouth, short red urine. Tongue pulse: tongue red fur yellow greasy, pulse slippery number. The determination of the above 8 syndromes can be made if there are 2 main symptoms and 1-2 secondary symptoms. The tongue pulse is for reference only.\n4. The patients who can tolerate Baitouweng Decoction;\n5. The patients who tolerance to colonoscopy and TET;\n6. The patients who know and agree to participate in the clinical trial.\n\nExclusion Criteria:\n\n1. The patients are complicated with other diseases that may cause diarrhea, such as infectious colitis, radiation enteritis, Crohn's disease, etc.\n2. Patients with heart, brain, lung, liver, kidney and other serious diseases;\n3. Patients do not cooperate to complete the clinical trial process;\n4. Other cases considered unsuitable for inclusion.",{"count":578,"type":21},144,[59],"Baitouweng Decoction is traditionally used to treat large intestine damp-heat syndrome of ulcerative colitis (UC) by oral administration and rectal enema.The project applicant's invention of transendoscopic entral tubing (TET) has been used in Baitouweng Decoction for the treatment of UC across the whole colon, however, the efficacy have not been reported and the underlying mechanism is still unclear. Compared with oral and rectal enema, Baitouweng Decoction by colon TET can improve the therapeutic effect by increasing the concentration of drugs in the whole colon, which need to be verified. This project will reveal the prescription effect and drug-microbiome interaction mechanism of whole colon repeated administration of Baitouweng Decoction in the treatment of UC through clinical randomized controlled studies, deep intestinal dynamic sampling, integrated analysis of multi-omics and TCM prescription metabolomics studies, and provide key scientific basis for the establishment of a new approach of whole colon repeated administration of TCM and a new strategy for the treatment of UC.",[582],"Ulcerative Colitis",[584,585,586,587,588],"Baitouweng Decoction","Formula-to-Syndrome Effect","Ulcerative colitis","Pharmacomicrobiomics","Colon delivery","2024-05-20",{"date":591,"type":39},"2024-05-21",{"date":593,"type":21},"2024-05",{"date":595,"type":21},"2026-12-30",{"name":45,"class":46},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":22,"phases":607,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":47},"100544691","washed-microbiota-transplantation-for-allergic-rhinitis-100544691","NCT06372184","Washed Microbiota Transplantation for Allergic Rhinitis","Efficacy and Safety of Washed Microbiota Transplantation for Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n1. Age 18-65 years old.\n2. Meets the diagnostic criteria for allergic rhinitis.\n3. rTNSS score greater than or equal to 6 points.\n4. The subject or his\u002Fher legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\n   \\-\n\nExclusion Criteria:\n\n1. Patients with acute nasosinusitis or upper respiratory tract infection.\n2. Patients diagnosed with chronic sinusitis, nasal septum deviation, nasal polyps, nasal tumors, and other nasal diseases or have undergone nasal surgery.\n3. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the past two weeks.\n4. Patients with poor lung function.\n5. Patients with severe liver, kidney, and heart diseases\n6. Patients with known psychiatric or neurological diseases.\n7. Patients who use antihistamines, glucocorticoids, decongestants, mast cell membrane stabilizers, leukotriene antagonists in the past two weeks.\n8. According to the judgment of the investigator, the subjects are not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subjects.\n\n   \\-","65 Years",{"count":606,"type":21},32,[24],"Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.",[610],"Rhinitis, Allergic",[89,612,613,614,92],"allergic rhinitis","reflective total nasal symptom score","rhinoconjunctivitis quality of life questionnaire score","2024-05-05",{"date":617,"type":39},"2024-05-07",{"date":619,"type":21},"2024-06-01",{"date":621,"type":21},"2029-10-01",{"name":45,"class":46},""]